A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Yohimbine
Danaparoid
The risk or severity of hyperkalemia can be increased when Danaparoid is combined with Fimasartan.
Yohimbine
Bufuralol
The risk or severity of hyperkalemia can be increased when Bufuralol is combined with Fimasartan.
Yohimbine
Nilvadipine
The risk or severity of hyperkalemia can be increased when Nilvadipine is combined with Fimasartan.
Yohimbine
Dotarizine
The risk or severity of hyperkalemia can be increased when Dotarizine is combined with Fimasartan.
Yohimbine
Sulodexide
The risk or severity of hyperkalemia can be increased when Sulodexide is combined with Fimasartan.
Yohimbine
Nylidrin
The risk or severity of hyperkalemia can be increased when Nylidrin is combined with Fimasartan.
Yohimbine
Seletracetam
The risk or severity of hyperkalemia can be increased when Seletracetam is combined with Fimasartan.
Yohimbine
Methsuximide
The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Fimasartan.
Yohimbine
Clevidipine
The risk or severity of hyperkalemia can be increased when Clevidipine is combined with Fimasartan.
Yohimbine
Celiprolol
The risk or severity of hyperkalemia can be increased when Celiprolol is combined with Fimasartan.
Yohimbine
Fluspirilene
The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Fimasartan.
Yohimbine
Flunarizine
The risk or severity of hyperkalemia can be increased when Flunarizine is combined with Fimasartan.
Yohimbine
Cyclandelate
The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Fimasartan.
Yohimbine
Prenylamine
The risk or severity of hyperkalemia can be increased when Prenylamine is combined with Fimasartan.
Yohimbine
Penicillin G Acyl-Serine
The risk or severity of hyperkalemia can be increased when Penicillin G Acyl-Serine is combined with Fimasartan.
Yohimbine
Canrenone
The risk or severity of hyperkalemia can be increased when Fimasartan is combined with Canrenone.
Yohimbine
Canrenoic acid
The risk or severity of hyperkalemia can be increased when Canrenoic acid is combined with Fimasartan.
Yohimbine
Cilazaprilat
The risk or severity of adverse effects can be increased when Fimasartan is combined with Cilazaprilat.
Yohimbine
Moxonidine
The risk or severity of adverse effects can be increased when Fimasartan is combined with Moxonidine.
Yohimbine
Indoramin
The risk or severity of adverse effects can be increased when Fimasartan is combined with Indoramin.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3